4
Changes in Ownership
NEKTAR THERAPEUTICS Filed Acc 0001209191-21-065229
Chief R&D Officer sold 20,869 shares at $13.16 ($274,636)
- Chief R&D Officer acquired 40,150 shares (grant or award)
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Zalevsky Jonathan Chief R&D Officer | 2021-11-15 | Grant or award | +40,150 | 252,953 | D: show line 1 in the form | ||
| Zalevsky Jonathan Chief R&D Officer | 2021-11-16 | Sale | −20,869 | $13.16 | $274,636 | 232,084 | D: show line 2 in the form |
| Open-market sales · 20,869 sh · avg $13.16 · $274,636 | |||||||
Loading xslF345X03/doc4.xml…